Janagliflozin: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|An article about the antidiabetic medication Janagliflozin}} | |||
{{Drugbox | |||
| verifiedrevid = 123456789 | |||
| image = Janagliflozin.svg | |||
| image_size = 200px | |||
| image_alt = Structural formula of Janagliflozin | |||
}} | |||
'''Janagliflozin''' is an oral antidiabetic medication used in the management of [[type 2 diabetes mellitus]]. It belongs to the class of drugs known as [[sodium-glucose co-transporter 2 inhibitors]] (SGLT2 inhibitors), which work by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in the urine. | |||
== | ==Mechanism of Action== | ||
Janagliflozin | Janagliflozin functions by inhibiting the [[sodium-glucose co-transporter 2]] (SGLT2) in the proximal tubules of the [[kidney]]. This inhibition reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, leading to increased urinary glucose excretion and a reduction in blood glucose levels. | ||
== | ==Pharmacokinetics== | ||
Janagliflozin is administered orally and is rapidly absorbed from the gastrointestinal tract. It has a bioavailability of approximately 78% and reaches peak plasma concentrations within 1 to 2 hours after ingestion. The drug is extensively metabolized in the liver, primarily via the [[cytochrome P450]] enzyme system, and is excreted in both urine and feces. | |||
== | ==Clinical Use== | ||
Janagliflozin is | Janagliflozin is indicated for the treatment of [[type 2 diabetes mellitus]] in adults. It is often used in combination with other antidiabetic agents such as [[metformin]], [[sulfonylureas]], or [[insulin]] to achieve better glycemic control. The medication is not recommended for use in patients with [[type 1 diabetes mellitus]] or for the treatment of [[diabetic ketoacidosis]]. | ||
== | ==Side Effects== | ||
Janagliflozin | Common side effects of Janagliflozin include [[urinary tract infections]], [[genital mycotic infections]], and increased urination. More serious side effects can include [[ketoacidosis]], [[acute kidney injury]], and [[hypotension]]. Patients are advised to maintain adequate hydration to minimize the risk of dehydration and hypotension. | ||
== | ==Contraindications== | ||
Janagliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should also be used with caution in patients with a history of [[hypotension]] or [[electrolyte imbalance]]. | |||
[[ | ==Related pages== | ||
[[ | * [[Type 2 diabetes mellitus]] | ||
* [[Sodium-glucose co-transporter 2 inhibitors]] | |||
* [[Metformin]] | |||
* [[Insulin]] | |||
[[Category:Antidiabetic drugs]] | |||
[[Category:SGLT2 inhibitors]] | |||
<gallery> | |||
File:Janagliflozin.svg|Janagliflozin | |||
</gallery> | |||
Latest revision as of 01:39, 20 February 2025
An article about the antidiabetic medication Janagliflozin
| Janagliflozin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Janagliflozin is an oral antidiabetic medication used in the management of type 2 diabetes mellitus. It belongs to the class of drugs known as sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors), which work by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in the urine.
Mechanism of Action[edit]
Janagliflozin functions by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubules of the kidney. This inhibition reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, leading to increased urinary glucose excretion and a reduction in blood glucose levels.
Pharmacokinetics[edit]
Janagliflozin is administered orally and is rapidly absorbed from the gastrointestinal tract. It has a bioavailability of approximately 78% and reaches peak plasma concentrations within 1 to 2 hours after ingestion. The drug is extensively metabolized in the liver, primarily via the cytochrome P450 enzyme system, and is excreted in both urine and feces.
Clinical Use[edit]
Janagliflozin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin to achieve better glycemic control. The medication is not recommended for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Side Effects[edit]
Common side effects of Janagliflozin include urinary tract infections, genital mycotic infections, and increased urination. More serious side effects can include ketoacidosis, acute kidney injury, and hypotension. Patients are advised to maintain adequate hydration to minimize the risk of dehydration and hypotension.
Contraindications[edit]
Janagliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should also be used with caution in patients with a history of hypotension or electrolyte imbalance.
Related pages[edit]
-
Janagliflozin
